Kelly Thomas

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Shuo Feng, Daniel J. Phillips, Thomas White et al. · Nature Medicine · 2021 · 1.2K citations · Full text

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2021 · 1.2K citations · Full text

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett, Sandra Belij‐Rammerstorfer, Christina Dold et al. · Nature Medicine · 2020 · 334 citations · Full text

Vaccination, Phase 1/2, Vaccine Development +7

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

Kevin R. Bewley, Naomi S. Coombes, Luc Gagnon et al. · Nature Protocols · 2021 · 317 citations · Full text

Virus Neutralization Assays, Viral Diagnostics, Viral Pathogenesis +6